Skip to content
Acenocoumarol
Acenocoumarol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vitamin K epoxide reductase complex subunit 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AA: Vitamin k antagonists
— B01AA07: Acenocoumarol
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——2136
Pulmonary embolismD011655EFO_0003827I26—121—3
StrokeD020521EFO_0000712I63.9———2—2
Venous thromboembolismD054556EFO_0004286I74—111—2
Blood coagulation disordersD001778EFO_0009314D68.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Venous thrombosisD020246HP_0004936I82.40—11—12
Intracranial hemorrhagesD020300EFO_0000551I62——1——1
Hypertensive intracranial hemorrhageD020299——1——1
Subarachnoid hemorrhageD013345EFO_0000713I60——1——1
Subdural hematomaD006408HP_0100309——1——1
Cerebral intraventricular hemorrhageD000074042——1——1
Atrial flutterD001282EFO_0003911——1——1
Antiphospholipid syndromeD016736EFO_0002689D68.61——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I21————11
Embolic strokeD000083262————11
Healthy volunteers/patients—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameACENOCOUMAROL
INNacenocoumarol
Description
Acenocoumarol is a hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. It has a role as an anticoagulant and an EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor. It is a C-nitro compound, a hydroxycoumarin and a methyl ketone.
Classification
Small molecule
Drug classanticoagulants (dicumarol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O
Identifiers
PDB—
CAS-ID152-72-7
RxCUI154
ChEMBL IDCHEMBL397420
ChEBI ID53766
PubChem CID54676537
DrugBankDB01418
UNII IDI6WP63U32H (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
VKORC1
VKORC1
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
79001
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Q9BQB6
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000225969CYP4F2, 1297G>A, Val433Metdrug response2021-03-241A
VCV000002211VKORC1, -1639G>Adrug response2021-11-191A
VCV000037344VKORC1, 174-136C>Tdrug response2021-03-291B
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,724 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,296 adverse events reported
View more details